CINECA IRIS Institutional Research Information System

ROMEI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.123
EU - Europa 4.873
AS - Asia 1.093
AF - Africa 261
SA - Sud America 31
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
Totale 13.394
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.957
IT - Italia 1.764
DE - Germania 1.029
SE - Svezia 879
CN - Cina 538
BG - Bulgaria 317
GB - Regno Unito 301
CI - Costa d'Avorio 191
CA - Canada 157
SG - Singapore 149
AT - Austria 127
VN - Vietnam 125
IN - India 108
UA - Ucraina 102
RU - Federazione Russa 91
TR - Turchia 88
FI - Finlandia 82
SN - Senegal 64
CH - Svizzera 44
HK - Hong Kong 37
FR - Francia 29
BE - Belgio 23
BR - Brasile 20
GR - Grecia 13
NL - Olanda 13
ES - Italia 12
IR - Iran 11
PL - Polonia 10
JP - Giappone 8
EU - Europa 7
RO - Romania 7
AU - Australia 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
IL - Israele 6
ID - Indonesia 5
PK - Pakistan 5
CO - Colombia 4
HU - Ungheria 4
IE - Irlanda 4
RS - Serbia 4
CL - Cile 3
KR - Corea 3
MX - Messico 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
BH - Bahrain 2
DK - Danimarca 2
EE - Estonia 2
EG - Egitto 2
NO - Norvegia 2
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
DZ - Algeria 1
GE - Georgia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NG - Nigeria 1
PT - Portogallo 1
SA - Arabia Saudita 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 13.394
Salva come PNG Salva come JPEG
Città #
Fairfield 819
Woodbridge 795
Ann Arbor 719
Chandler 615
Houston 574
Ashburn 461
Seattle 348
Cambridge 320
Sofia 316
Milan 291
Wilmington 290
Beijing 222
Abidjan 191
New York 187
Serra 174
Princeton 144
Ottawa 143
Jacksonville 126
Lawrence 118
Vienna 118
Medford 96
Pisa 84
Des Moines 81
Nanjing 73
Florence 72
Rome 72
Izmir 70
London 69
Dearborn 66
Dakar 64
Dong Ket 57
Boulder 54
Bremen 53
Frankfurt am Main 48
Lancaster 44
Redwood City 43
San Diego 41
Bern 37
Washington 33
Hong Kong 32
Jüchen 24
Naples 24
Redmond 24
Grafing 23
Nanchang 22
Shenyang 22
Changsha 21
Brussels 20
Bologna 19
Shanghai 19
Los Angeles 17
Kunming 16
Hangzhou 15
Hebei 15
Norwalk 15
Tianjin 15
Bengaluru 13
Hefei 13
Jiaxing 13
Pune 13
Verona 13
Chiesina Uzzanese 11
Jaboatão 11
Nürnberg 11
Ogden 11
Dallas 10
Düsseldorf 10
Genoa 10
Mumbai 10
Napoli 10
Sacile 10
Trieste 10
Bhavnagar 9
Detroit 9
Phoenix 9
Singapore 9
Turin 9
Wuhan 9
Jinan 8
Kocaeli 8
Parma 8
Bari 7
Boardman 7
Buffalo 7
Chengdu 7
Cuneo 7
Montale 7
Ningbo 7
Guangzhou 6
Indiana 6
Istanbul 6
La Spezia 6
Lucca 6
Messina 6
Munich 6
San José 6
Scandicci 6
Trevignano 6
Acerra 5
Angri 5
Totale 8.847
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 681
Medullary thyroid carcinoma in children 406
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 214
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 191
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 182
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 171
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 169
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 165
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 160
null 157
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 156
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 155
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 150
Targeted Therapy in Thyroid Cancer: State of the Art 149
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 147
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 146
null 145
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 145
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 141
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 141
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 139
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 138
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 137
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 136
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 132
RET point mutations in Thyroid Carcinoma 132
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 132
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 132
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 131
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 131
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 129
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 126
Genome-wide association study on differentiated thyroid cancer. 125
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 125
null 122
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 122
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 121
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 120
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 120
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 119
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 117
Post-surgical follow-up of differentiated thyroid cancer. 116
Inherited variants in genes somatically mutated in thyroid cancer 116
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 115
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 114
null 114
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. 111
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 110
Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. 109
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 109
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 109
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 108
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 105
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 105
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma 105
The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans 104
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 104
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 103
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 102
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 102
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association 101
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 100
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 99
null 99
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 98
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 97
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 97
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk 97
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 96
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 93
Correction: Inherited variants in genes somatically mutated in thyroid cancer 93
Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype 91
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 91
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 90
RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults 90
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 87
RET /PTC translocations and clinico-pathological features in human papillary thyroid carcinoma 86
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 85
RET proto-oncogene mutations in thyroid carcinomas: clinical relevance 84
null 84
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 84
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1 83
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 82
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 81
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 81
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 79
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 79
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 79
Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations 78
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association 77
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 76
Runs of homozygosity and inbreeding in thyroid cancer 76
null 75
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 75
Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system 75
Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). 74
null 72
L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide 71
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma 71
null 70
Totale 12.114
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.897
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019859 0 0 0 0 0 0 0 0 0 244 340 275
2019/20202.796 310 184 213 187 286 313 272 199 231 215 321 65
2020/20211.169 120 89 100 49 75 81 104 98 119 87 65 182
2021/20221.579 59 85 33 103 333 185 46 82 77 61 116 399
2022/20232.529 289 386 186 190 218 267 56 197 487 43 164 46
2023/20241.517 184 169 216 125 212 262 133 104 67 45 0 0
Totale 13.714